Mannkind reported $12.92M in Cost of Sales for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cost Of Sales Change
Adma Biologics ADMA:US $ 26.14M 0.7M
Biocryst Pharmaceuticals BCRX:US $ 0.25M 0.01M
ChemoCentryx CCXI:US 803K 598K
Dynavax Technologies DVAX:US $ 83.37M 43.41M
Eli Lilly And LLY:US $ 1430.5M 641.6M
Halozyme Therapeutics HALO:US $ 33.94M 18.02M
Insmed INSM:US $ 16.4M 4.2M
JAZZ PHA JAZZ:US $ 124.21M 8.92M
Karyopharm Therapeutics KPTI:US $ 939K 487K
MacroGenics MGNX:US 2.4M 2.35M
Mannkind MNKD:US $ 12.92M 1.92M
Merk MRK:US $ 3698M 1636M
Novavax NVAX:US 271.08M 255.87M
Novo Nordisk A Fs NVO:US $ 6069M 848M
Peregrine Pharmaceuticals PPHM:US $ 27.58M 3.33M
Pfizer PFE:US $ 8671M 1339M